Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/33816
BLOOD-STAGE PLASMODIUM VIVAX ANTIBODY DYNAMICS IN A LOW TRANSMISSION SETTING: A NINE YEAR FOLLOW-UP STUDY IN THE AMAZON REGION
Autor(es)
Pires, Camilla Valente
Alves, Jéssica Rafaela dos Santos
Lima, Bárbara Andreza Soares
Paula, Ruth Barros de
Costa, Helena Lott
Torres, Leticia de Menezes
Sousa, Taís Nobrega
Soares, Irene Silva
Sanchez, Bruno A. M.
Fontes, Cor Jésus Fernandes
Ntumngia, Francis B.
Adams, John H.
Kano, Flora Satiko
Carvalho, Luzia Helena de
Alves, Jéssica Rafaela dos Santos
Lima, Bárbara Andreza Soares
Paula, Ruth Barros de
Costa, Helena Lott
Torres, Leticia de Menezes
Sousa, Taís Nobrega
Soares, Irene Silva
Sanchez, Bruno A. M.
Fontes, Cor Jésus Fernandes
Ntumngia, Francis B.
Adams, John H.
Kano, Flora Satiko
Carvalho, Luzia Helena de
Afiliação
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas. Departamento de Análises Clínicas e Toxicológicas. São Paulo, SP, Brasil.
Universidade Federal de Mato Grosso. Instituto de Ciências da Saúde. Sinop, Mato Grosso, Brasil.
Universidade Federal de Mato Grosso. Hospital Júlio Muller. Cuiabá, MT, Brasil
Center for Global Health and Infectious Diseases Research. Department of Global Health. College of Public Health. University of South Florida. Tampa, FL, USA.
Center for Global Health and Infectious Diseases Research. Department of Global Health. College of Public Health. University of South Florida. Tampa, FL, USA.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas. Departamento de Análises Clínicas e Toxicológicas. São Paulo, SP, Brasil.
Universidade Federal de Mato Grosso. Instituto de Ciências da Saúde. Sinop, Mato Grosso, Brasil.
Universidade Federal de Mato Grosso. Hospital Júlio Muller. Cuiabá, MT, Brasil
Center for Global Health and Infectious Diseases Research. Department of Global Health. College of Public Health. University of South Florida. Tampa, FL, USA.
Center for Global Health and Infectious Diseases Research. Department of Global Health. College of Public Health. University of South Florida. Tampa, FL, USA.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil.
Resumo em Inglês
Plasmodium vivax remains a global health problem and its ability to cause relapses and subpatent infections challenge control and elimination strategies. Even in low malaria transmission settings, such as the Amazon basin, where progress in malaria control has caused a remarkable reduction in case incidence, a recent increase in P. vivax transmission demonstrates the continued vulnerability of P.vivax-exposed populations. As part of a search for complementary approaches to P.vivax surveillance in areas in which adults are the majority of the exposed-population, here we evaluated the potential of serological markers covering a wide range of immunogenicity to estimate malaria transmission trends. For this, antibodies against leading P. vivax blood-stage vaccine candidates were assessed during a 9 year follow-up study among adults exposed to unstable malaria transmission in the Amazon rainforest. Circulating antibody levels against immunogenic P. vivax proteins, such as the Apical Membrane Antigen-1, were a sensitive measure of recent P. vivax exposure, while antibodies against less immunogenic proteins were indicative of naturally-acquired immunity, including the novel engineered Duffy binding protein II immunogen (DEKnull-2). Our results suggest that the robustness of serology to estimate trends in P.vivax malaria transmission will depend on the immunological background of the study population, and that for adult populations exposed to unstable P.vivax malaria transmission, the local heterogeneity of antibody responses should be considered when considering use of serological surveillance.
Compartilhar